Aging, Author Interviews, Geriatrics, NEJM, Pulmonary Disease, Respiratory, Vaccine Studies / 09.03.2023
NEJM: GSK Vaccine Found Highly Effective Against RSV Respiratory Disease in Older Adults
MedicalResearch.com Interview with:
Veronica Hulstrøm MD, PhD
Senior Director
Clinical Project Lead for RSV Older Adults
GSK
MedicalResearch.com: What is the background for this study?
Response: The AReSVi-006 phase III trial is designed to investigate the efficacy and safety of GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. The phase III trial is a randomized, placebo-controlled, double-blind, international trial with 24,966 participants who received either the investigational vaccine or placebo.
(more…)